3.2 Process and methods - Appraisal

Since reimbursement decisions for new health technologies can be controversial, best practice separates evidence assessment, appraisal, and decision-making.

Appraisal committees—sometimes within an HTA body but not always—review the evidence assessment along with other factors such as local health policies, societal values, and patient testimony. In some cases, these committees also play a role in decision-making.

HTA processes typically result in a recommendation to either list or not list a technology for reimbursement in an insurance-based system or recommend its use in a taxation-based national health service. Sometimes, listing comes with restrictions, such as limiting use to patients with more severe illness.

Consider the following diagram:

Figure 1: Diagram of HTA process

Determining whether an intervention will reduce heart attack rates, cause side effects, or increase healthcare costs requires judgments about the robustness of evidence. There are always uncertainties, and HTA bodies must use sound scientific judgment and consistent, transparent approaches to ensure defensible decisions. Given the multidisciplinary nature of HTA, expertise from fields like epidemiology, sociology, economics, ethics, and law is necessary to support analyses.

However, making decisions also requires recognizing what society and patients value. For example, is it valuable to reduce heart attack rates, and at what cost to the health system or society at large? It’s widely accepted that individual recommendations lack the full perspective needed, which is why deliberative appraisal is used—this involves a committee that considers multiple viewpoints to arrive at a transparent and well-supported decision.

HTA bodies often prioritize the magnitude of health outcomes from well-designed clinical trials, especially with relevant comparators. Economic considerations also play a key role, including budget impact—the total cost added to the health system, factoring in potential savings from reduced hospital admissions or other benefits.

While incremental health benefits often come with costs, the impact on resource allocation must also be considered. Health improvements may not always reduce healthcare expenditures, but savings may occur in other areas of the budget. HTA bodies must make difficult decisions about how to allocate finite resources while considering long-term societal health benefits.

Neutrality is essential in the committee structure, and members must declare any conflicts of interest or decline participation if necessary. Some HTA bodies use an ethical framework for broader stakeholder review, allowing for appeals from pharmaceutical companies, clinicians, or patients.

Citizen input is rarely sought, but in some cases, like the UK’s NICE Citizens’ Council, it can help inform decisions on societal value judgments. The council has advised on various issues since 2002.

Topics considered by NICE’s Citizens’ Council.